Eledon Pharmaceuticals
ELDN
29 hedge funds and large institutions have $19.8M invested in Eledon Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.
33% more call options, than puts
Call options by funds: $4K | Put options by funds: $3K
20% more capital invested
Capital invested by funds: $16.5M → $19.8M (+$3.29M)
1.83% more ownership
Funds ownership: 37.82% → 39.65% (+1.8%)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$488K |
| 2 |
AC
Armistice Capital
New York
|
+$193K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$90.7K |
| 4 |
MIM
Marco Investment Management
Atlanta,
Georgia
|
+$44.3K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$35.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$66.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$21.2K |
| 3 |
Millennium Management
New York
|
-$16K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$5.75K |
ELDN Hedge Fund Activity: Q1 2024 in Review
29 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2024, worth a combined $19.8M — up 20% from $16.5M a quarter earlier.
Fund positioning in ELDN was balanced in Q1 2024: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $488K. The largest seller was Woodline Partners, cutting an estimated $66.7K.
- 29 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $19.8M of Eledon Pharmaceuticals stock for Q1 2024, up 20% quarter-over-quarter.
- 3 funds opened new Eledon Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of 0 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2024 was Vanguard Group, an estimated $488K added.
- The largest Eledon Pharmaceuticals seller in Q1 2024 was Woodline Partners, an estimated $66.7K sold.
Based on aggregated 13F filings for Q1 2024.